TGFB1 and neoplasm: It was our hypothesis that a local release of TGF‐β inhibitor within the tumor microenvironment could promote neutrophil polarization into the antitumor N1 phenotype, and enhance pancreatic cancer response to combined IRE and αPD1 treatment.